Early measurements of serum ustekinumab concentrations predict efficacy for remission in patients with Crohn's disease

Ustekinumab concentrations at week 4 and beyond have been associated with treatment outcomes in patients with Crohn’s disease. However, the exposure-response relationship during the first 2 weeks of treatment is unclear. We summarize the @GIJournal discussion held on November 10, 2021, during which we discussed the article by Hanžel et al. entitled “Peak concentrations of ustekinumab after intravenous induction therapy identify patients with Crohn's disease likely to achieve endoscopic and biochemical remission”. Key findings were critically reviewed by our experts E. V. Loftus, Jr., and A. Charabaty, and the session was moderated by S. Mahmood.